EDAP TMS S.A. Dossier - Source-backed chat

EDAP TMS S.A.

EDAPNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.29

Intrinsic Value

Valuation withheldThis company reports its financial statements in one currency and its shares are priced in another, so the two cannot be compared as they stand. The valuation returns when the statements and the price have been brought to one currency.

Market Price $4.13Price as of 15 Oct 2026

Data confidenceNot applicable

Market Cap $195M

Enterprise Value $211.5M

Shares Outstanding 37.5M diluted

Moat Rating None

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

EDAP TMS S.A. (operating as FocalTherics) is undergoing a major strategic transformation to become a high-growth, pure-play robotic focal therapy company. By rebranding to FocalTherics, changing its Nasdaq ticker to FOCL, and planning to classify its legacy, low-margin ESWL and Distribution segments as discontinued operations starting in Q2 2026, the company is unlocking significant shareholder value. The core investment thesis centers on the rapid adoption of its flagship Focal One Robotic HIFU platform, which is currently the fastest-growing focal therapy treatment and the #1 ablation technology for prostate cancer. Strong clinical validation, such as the landmark HIFI-2 study, and strategic collaborations (e.g., with Telix Pharmaceuticals) position the company to capture a substantial share of the expanding therapeutic ultrasound market.

This section is the 12-month view: analyst targets and the scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.00

Mean target$8.50

High · most bullish analyst$15.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The transition of legacy segments to discontinued operations causes short-term reporting complexities and operational friction. Increased sales and marketing expenses to support the Focal One rollout widen operating losses more than anticipated, straining cash reserves. Competitors with alternative focal therapies (such as irreversible electroporation or transurethral ultrasound ablation) gain market share, slowing down Focal One system placements.

Base CaseCentral scenario

The core HIFU business continues its strong momentum, achieving the projected 2026 revenue guidance of $50.0 million to $54.0 million (representing 34% to 45% year-over-year growth). The successful transition to discontinued operations for legacy segments improves overall gross margins and highlights the high-growth profile of the continuing robotic focal therapy business. Increased utilization of the installed base and steady capital placements in the U.S. and Europe drive the stock toward the consensus target.

Bull CaseUpside scenario

The bull case for EDAP TMS (FocalTherics) centers on its strategic transition into a pure-play High-Intensity Focused Ultrasound (HIFU) company by divesting its legacy ESWL and distribution businesses. This shift is anchored by the accelerating clinical adoption of its flagship Focal One Robotic HIFU platform for prostate cancer, supported by strong clinical evidence (such as the FARP trial demonstrating non-inferiority to radical prostatectomy) and favorable reimbursement trends (including a Category 1 CPT code and increased Medicare outpatient payments). Furthermore, the company is expanding its total addressable market into high-potential indications like benign prostatic hyperplasia (BPH) and deep infiltrating endometriosis, targeting a combined addressable opportunity of over 4 million annual procedures and a $10 billion market.

Scenarios are anchored to street consensus at the research date, with our rationale.

Key Investment Merits

Strong growth in core HIFU revenue, which surged 78% year-over-year to $11.6 million in Q1 2026.
Strategic pure-play transformation through the FocalTherics rebranding and divestiture/discontinuation of legacy non-core segments.
Robust clinical backing from the landmark HIFI-2 study, validating Focal One as a breakthrough salvage treatment.
High-profile collaborations, such as the partnership with Telix Pharmaceuticals to integrate molecular imaging with robotic HIFU.

Key Investment Risks

Widening operating losses ($7.4 million in Q1 2026) and cash burn as the company funds its global commercial expansion.
Intense competition in the prostate cancer treatment space from established robotic surgery platforms and alternative ablation technologies.
Regulatory and reimbursement hurdles associated with expanding Focal One into new clinical indications.

Thesis Invalidation Triggers

A significant slowdown in Focal One system placements or procedure volume growth in the key U.S. market.
Failure to obtain shareholder approval for the legal name change or unexpected complications in divesting legacy segments.
Negative clinical trial outcomes or regulatory delays for new therapeutic indications.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.